Key Points
- Insider sale: Director Ramkumar Mandalam sold 11,570 shares on Dec. 10 at an average price of $9.99 for about $115,584, reducing his stake by 12.53% to 80,758 shares; the transaction was disclosed in an SEC filing.
- Recent results: CryoPort beat expectations last quarter with a ($0.18) EPS versus a ($0.23) estimate and revenue of $44.23M (vs. $41.22M), but the company remains unprofitable with analysts forecasting about -$0.99 EPS for the year.
- Market/analyst context: The company has a $470.7M market cap, a consensus rating of "Moderate Buy" with an average price target of $12.83, and high institutional ownership at 92.9% amid mixed analyst opinions.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 11,570 shares of the company's stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the completion of the transaction, the director owned 80,758 shares in the company, valued at approximately $806,772.42. The trade was a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
CryoPort Stock Performance
NASDAQ:CYRX opened at $9.40 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The business has a fifty day simple moving average of $9.43 and a two-hundred day simple moving average of $8.48. CryoPort, Inc. has a 1 year low of $4.58 and a 1 year high of $11.44. The company has a market capitalization of $470.66 million, a P/E ratio of 8.03 and a beta of 1.51.
CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The firm had revenue of $44.23 million for the quarter, compared to analysts' expectations of $41.22 million. On average, analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current year.
Institutional Trading of CryoPort
A number of hedge funds and other institutional investors have recently bought and sold shares of CYRX. Nisa Investment Advisors LLC lifted its stake in CryoPort by 299.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after purchasing an additional 2,729 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CryoPort in the third quarter worth $53,000. ProShare Advisors LLC purchased a new stake in shares of CryoPort in the second quarter worth $75,000. Finally, AlphaQuest LLC bought a new stake in CryoPort during the third quarter valued at $79,000. Institutional investors own 92.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on CYRX shares. Weiss Ratings reiterated a "sell (d+)" rating on shares of CryoPort in a research note on Monday. BTIG Research raised their price objective on shares of CryoPort from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, September 18th. Needham & Company LLC boosted their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, November 5th. Finally, UBS Group increased their target price on CryoPort from $11.00 to $12.50 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.83.
Check Out Our Latest Stock Analysis on CryoPort
About CryoPort
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
